Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response

Mytsyk, Yulian; Pasichnyk, S. M.; Dutka, Ihor; Dats, I.; Vorobets, D. Z.; Skrzypczyk, M.; Uteuliyev, Y; Botíková, Andrea; Gazdíková, Katarína; Kubatka, Peter; Urdzík, Peter; Kružliak, Peter

doi:10.1007/s10238-020-00612-9

Cited by 7 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By analyzing the ADC values before and after systemic treatment, they found that changes in ADC values were correlated with treatment response. These results suggest that DW-MRI, specifically the ADC parameter, can serve as a useful tool for predicting early therapeutic response in mRCC patients, facilitating treatment monitoring and decision making [108].…”

Section: Retrospective Studiesmentioning

confidence: 86%

Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring

Dani,

Rich,

Kumar

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: Challenges remain in determining the most effective treatment strategies and identifying patients who would benefit from adjuvant or neoadjuvant therapy in renal cell carcinoma. The objective of this review is to provide a comprehensive overview of biomarkers in metastatic renal cell carcinoma (mRCC) and their utility in prediction of treatment response, prognosis, and therapeutic monitoring in patients receiving systemic therapy for metastatic disease. Methods: A systematic literature search was conducted using the PubMed database for relevant studies published between January 2017 and December 2022. The search focused on biomarkers associated with mRCC and their relationship to immune checkpoint inhibitors, targeted therapy, and VEGF inhibitors in the adjuvant, neoadjuvant, and metastatic settings. Results: The review identified various biomarkers with predictive, prognostic, and therapeutic monitoring potential in mRCC. The review also discussed the challenges associated with anti-angiogenic and immune-checkpoint monotherapy trials and highlighted the need for personalized therapy based on molecular signatures. Conclusion: This comprehensive review provides valuable insights into the landscape of biomarkers in mRCC and their potential applications in prediction of treatment response, prognosis, and therapeutic monitoring. The findings underscore the importance of incorporating biomarker assessment into clinical practice to guide treatment decisions and improve patient outcomes in mRCC.

show abstract

Section: Retrospective Studiesmentioning

confidence: 86%

Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring

Dani,

Rich,

Kumar

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Previously, the value of ADC in improving the differential diagnosis, histologic subtyping, and grade differentiation of RCC using MRI [ 22 ] and in assessing RCC systemic treatment response with tyrosine kinase inhibitor was demonstrated [ 18 ]. In the current study we ana-lysed the performance of ADC of DWI in the diagnostics of locally recurrent RCC.…”

Section: Discussionmentioning

confidence: 99%

“…All patients of the comparison group after inclusion into this study were followed up using MRI for at least 2 years; during this period we registered no imaging features of RCC LR. We used the MR-data of healthy volunteers (control group) from another study as reference values of ADC of normal renal parenchyma ( n = 25) [ 18 ].…”

Section: Methodsmentioning

confidence: 99%

Local recurrence of renal cell carcinoma after partial nephrectomy: applicability of the apparent diffusion coefficient of MRI as an imaging marker – a multicentre study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Purpose The goal of the study was an assessment of the diagnostic performance of diffusion-weighted images (DWI) and apparent diffusion coefficient (ADC) of magnetic resonance imaging (MRI) in distinguishing local recurrence (LR) of renal cell carcinoma (RCC) from benign conditions after partial nephrectomy. Material and methods Thirty-nine patients after partial nephrectomy for solid RCC were enrolled in the study. Patients were followed up using MRI, which included DWI sequence ( b = 800 s/mm 2 ). All patients with MRI features of LR were included in the main group ( n = 14) and patients without such features – into the group of comparison ( n = 25). Apparent diffusion coefficient (ADC) values of suspicious lesions were recorded. In all patients with signs of locally recurrent RCC, surgical treatment was performed followed by pathologic analysis. Results The mean ADC values of recurrent RCC demonstrated significantly higher numbers compared to benign fibrous tissues and were 1.64 ± 0.15 × 10 -3 mm 2 /s vs. 1.02 ± 0.26 × 10 -3 mm 2 /s ( p < 0.001). The mean ADC values of RCCs’ LR and benign post-op changes in renal scar substantially differed from mean ADC values of healthy kidneys’ parenchyma; the latter was 2.58 ± 0.05 × 10 -3 mm 2 /s ( p < 0.001). In ROC analysis, the use of ADC with a threshold value of 1.28 × 10 -3 mm 2 /s allowed us to differentiate local recurrence of RCC from benign postoperative changes with 100% sensitivity, 80% specificity, and accuracy: AUC = 0.980 ( p < 0.001). Conclusions The apparent diffusion coefficient of DWI of MRI can be used as a potential imaging marker for the diagnosis of local recurrence of RCC.

show abstract

“…In contrast to CT and USG, mpMRI collects information not just about the spatial or textural parameters of the prostate lesion, but also about functional and pharmacokinetic aspects of PCa tissue. Currently, one of the most investigated MRI-based imaging markers of localized PCa is the apparent diffusion coefficient (ADC) measured from diffusion-weighted images (DWI), which represent the degree of restriction of Brownian motion of hydrogen molecules in cancer tissues [ 13 ]. According to recent meta-analyses, ADC values showed moderate accuracy in separating high-risk from low-risk PCa in accordance to ISUP grades (76.9% sensitivity, 77.0% specificity, AUC = 0.67) [ 14 ] and also allowed detection of extraprostatic extension of PCa with polled sensitivity and specificity 80.5% and 69.1%, respectively [ 15 ].…”

Section: Radiomics: Imaging Markers In the Management Of Prostate Cancermentioning

confidence: 99%

Personalized management of prostate cancer: from molecular and imaging markers to radiogenomics

Mytsyk¹,

Borzhiyevskyy²,

Kobilnyk³

et al. 2022

Pol J Radiol

Self Cite

View full text Add to dashboard Cite

Purpose Prostate cancer (PCa) is the second most common cancer in men. The urge to guide treatment tactics based on personal clinical risk factors has evolved in the era of human genome sequencing. To date, personalized approaches to managing PCa patients have not yet been developed. Radiogenomics is a relatively new term, used to refer to the study of genetic variation associated with imaging features of the tumour in order to improve the prognostication of the disease course. Material and methods The study is a review of recent knowledge regarding potential clinical applications of radiogenomics in personalized treatment of PCa. Results Recent investigations have proven that by combining data on individual genetic tumour features, and radiomic profiling (radiologic-molecular correlation), with traditional staging procedures in order to personalize treatment of PCa, an improved prognostication of PCa course can be performed, and overtreatment of indolent cancer can be avoided. It was found that a combination of multiparametric MRI and gene expression data allowed the detection of radiomic features of PCa, which correlated with a number of gene signatures associated with adverse outcomes. It was revealed that several molecular markers may drive tumour upstaging, allowed the distinction between the PCa stages, and correlated with aggressiveness-related radiomic features. Conclusions The radiogenomics of PCa is not a comprehensively investigated area of oncourology. The combination of genomics and radiomics as integrative parts of precision medicine in the future has the potential to become the foundation for a personalized approach to the management of PCa.

show abstract

Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response

Cited by 7 publications

References 30 publications

Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring

Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring

Local recurrence of renal cell carcinoma after partial nephrectomy: applicability of the apparent diffusion coefficient of MRI as an imaging marker – a multicentre study

Personalized management of prostate cancer: from molecular and imaging markers to radiogenomics

Contact Info

Product

Resources

About